← Back to Search

CO2 Removal Device

Memsorb for Anesthesia Management (memsorb Trial)

N/A
Recruiting
Led By Orlando Hung, MD
Research Sponsored by DMF Medical Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
English-speaking patients
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during preoperative assessment
Awards & highlights

memsorb Trial Summary

This trialshows the drawbacks of chemical CO2 absorbers: they create harmful compounds, increasing cost and environmental impact, & require daily disposal of special waste. Sustainable management of anesthesia is a growing concern.

Who is the study for?
This trial is for English-speaking patients with a low to medium risk status (Class I, II, III) according to the American Society of Anesthesiologists. It's not suitable for pregnant individuals, high-risk patients (Class IV), those needing emergency surgery, or people with elevated brain pressure or severe respiratory diseases like COPD and asthma.Check my eligibility
What is being tested?
The study is testing 'memsorb', an innovative method aimed at removing CO2 from anesthetic circuits without using chemical granulate. This could potentially reduce harmful compounds, costs, environmental impact and the need for daily disposal of special waste.See study design
What are the potential side effects?
Since this summary does not provide specific side effects related to 'memsorb', it can be assumed that potential risks may be similar to those associated with standard anesthesia practices unless otherwise specified in detailed trial documents.

memsorb Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I speak English.

memsorb Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during preoperative assessment
This trial's timeline: 3 weeks for screening, Varies for treatment, and during preoperative assessment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
End Tidal CO2
Other outcome measures
Anaesthetic agent
Arterial blood CO2 partial pressure
Arterial blood oxygen saturation
+17 more

memsorb Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: memsorbExperimental Treatment1 Intervention
Patients agree to receive standard care but using memsorb, the new CO2 filter evaluated in this study.
Group II: ControlActive Control1 Intervention
Patients receive standard care with a standard CO2 absorber and agree to include their data in the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
memsorb
2014
N/A
~20

Find a Location

Who is running the clinical trial?

DMF Medical IncorporatedLead Sponsor
2 Previous Clinical Trials
70 Total Patients Enrolled
Orlando Hung, MDPrincipal InvestigatorNova Scotia Health Authority

Media Library

memsorb (CO2 Removal Device) Clinical Trial Eligibility Overview. Trial Name: NCT03014336 — N/A
Anesthesia Research Study Groups: memsorb, Control
Anesthesia Clinical Trial 2023: memsorb Highlights & Side Effects. Trial Name: NCT03014336 — N/A
memsorb (CO2 Removal Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03014336 — N/A
~24 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top